Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia

European Journal of Haematology

Volumn 83, Issue 3, 2009, Pages 208-214

  Molica, Stefano ^a   Digiesi, Giovanna ^b   Mirabelli, Rosanna ^a   Cutrona, Giovanna ^c   Antenucci, Anna ^b   Molica, Matteo ^f   Giannarelli, Diana ^b   Sperduti, Isabella ^b   Morabito, Fortunato ^d   Neri, Antonino ^e   Baldini, Luca ^e   Ferrarini, Manlio ^c  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Hematology Department   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CLL; Prognosis; Soluble CD26

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

AGED; ANTIGENS, CD26; ANTIGENS, CD38; DISEASE PROGRESSION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RISK; TIME FACTORS; TREATMENT OUTCOME; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 68849130111     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01273.x     Document Type: Article

References (30)

1. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998 161 : 55 70.
2. von Bonin A, Huhn J, Fleischer B. Dipeptidyl-peptidase IVCD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol Rev 1998 161 : 43 53.
3. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA. Regulation of the receptor specificity and function of the chemokine RANTES (Regulated on activation, normal T-cells expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997 186 : 1865 72.
4. Proost P, De Meester I, Schols D, Struyf S, Lambeir A-M, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J. Amino-terminal truncation of chemokines by CD26dipeptidyl-peptidase IV: conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998 273 : 7222 7.
5. Tanaka T, Umeki K, Yamamoto I, Sakamoto F, Noguchi S, Ohtaki S. CD26 (dipeptidyl peptidase IVDPPIV) as a novel molecular marker for differentiated thyroid carcinoma. Int J Cancer 1995 64 : 326 31.
6. Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A. Aberrant dipeptidyl peptidase IV (DPPIVCD26) expression in human hepatocellular carcinoma. J Hepatol 1997 27 : 337 45.
7. Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, Improta S, Sorio R, Monfardini S, Pinto A. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomasleukemias. Blood 1995 86 : 4617 26.
8. Narducci MG, Scala E, Bresin A, Caprini E, Picchio MC, Remotti D, et al. Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26dipeptidylpeptidase IV. Blood 2006 107 : 1108 15.
9. Bauvois B, De Meester I, Dumont J, et al. Constitutive expression of CD26dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br J Cancer 1999 79 : 1042 8.
10. Cro L, Morabito F, Zucal N, et al. CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. Hematol Oncol 2009 :. Feb 26. (Epub ahead of print).
11. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Sharpé S, De Meester I. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000 267 : 5608 13.
12. Busso N, Wagtmann N, Herling C, Chobaz-Péclat V, Bischof-Delaloye A, So A, Grouzmann E. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005 166 : 433 42.
13. Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ, de la Cadena MP. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 2000 83 : 1139 46.
14. de la Haba-Rodríguez J, Macho A, Calzado MA, Blázquez MV, Gómez MA, Muñoz EE, Aranda E. Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma. Neoplasma 2002 49 : 307 11.
15. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 111 : 5446 56.
16. Cutrona G, Colombo M, Matis S, Reverberi D, Dono M, Tarantino V, Chiorazzi N, Ferrarini M. B lymphocytes in humans express ZAP-70 when activated in vivo. Eur J Immunol 2006 36 : 558 69.
17. Cuneo A, Bigoni R, Rigolin GM, et al. Acquired deletion of the ataxia telengiactasia (ATM) locus in non-Hodgkin's lymphoma: correlation with clinicobiological features. J Clin Oncol 2000 18 : 2607 14.
18. Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991 78 : 895 9.
19. Horton T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003 43 : 121 37.
20. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343 : 1910 6.
21. Dang NH, Hafler DA, Schlossman SF, Breitmeyer JB. FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation. Cell Immunol 1990 125 : 42 57.
22. Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF, Morimoto C. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody: analysis of surface expression and human T cell activation. J Immunol 1990 145 : 3963 71.
23. Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. J Exp Med 1990 172 : 649 52.
24. Dang NH, Torimoto Y, Shimamura K, Tanaka T, Daley JF, Schlossman SF, Morimoto C. 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol 1991 147 : 2825 32.
25. Hegen M, Kameoka J, Dong R-P, Schlossman SF, Morimoto C. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 1997 90 : 257 64.
26. Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schrieber M, Dang NH, Letvin NL, Schlossman SF. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 1989 143 : 3430 9.
27. Ikushima H, Munakata Y, Ishii T, Iwata S, Terashima M, Tanaka H, Schlossman SF, Morimoto C. Internalization of CD26 by mannose 6-phosphateinsulin-like growth factor II receptor contributes to T cell activation. Proc Natl Acad Sci USA 2000 97 : 8439 44.
28. Dong R-P, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996 156 : 1349 55.
29. Patten PEM, Buggins AGM, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, Hamblin TJ, Devereux S. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008 111 : 5173 5181.
30. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008 22 : 211 9.